Cargando…
An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
BACKGROUND: Across Europe, methicillin-resistant Staphylococcus aureus (MRSA) is considered to be the primary cause of nosocomial pneumonia (NP). In Germany alone, approximately 14,000 cases of MRSA-associated NP occur annually, which may have a significant impact on health care resource use and ass...
Autores principales: | Patel, Dipen A, Michel, Andre, Stephens, Jennifer, Weber, Bertram, Petrik, Christian, Charbonneau, Claudie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216023/ https://www.ncbi.nlm.nih.gov/pubmed/25368526 http://dx.doi.org/10.2147/IDR.S68658 |
Ejemplares similares
-
Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
por: Patel, Dipen A, et al.
Publicado: (2014) -
Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010) -
Economic burden of inpatient and outpatient antibiotic treatment for methicillin-resistant Staphylococcus aureus complicated skin and soft-tissue infections: a comparison of linezolid, vancomycin, and daptomycin
por: Stephens, Jennifer M, et al.
Publicado: (2013) -
Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
por: Tian, Ye, et al.
Publicado: (2018) -
Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People’s Republic of China
por: Lesher, Beth, et al.
Publicado: (2016)